Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

VIRALEZE SPL7013 Virucidal (>99.99%) Against Delta Variant

  • New antiviral testing demonstrates SPL7013, the antiviral agent in VIRALEZE™ nasal spray, has potent virucidal activity against the globally significant Delta variant of SARS-CoV-2, reducing infectivity of the virus by >99.99% after 30 seconds of exposure
  • SPL7013, the antiviral agent in VIRALEZE™, has now been shown in laboratory studies to be virucidal against all four coronavirus SARS-CoV-2 Variants of Concern: Alpha, Beta, Gamma and Delta
  • These latest data further illustrate the broad-spectrum antiviral activity of SPL7013, which has been demonstrated against multiple respiratory viruses, including influenza and RSV, as well as its consistent and potent activity against multiple SARS-CoV-2 variants
  • VIRALEZE™ antiviral nasal spray is registered for sale in Europe and India, and available in certain markets online.

MELBOURNE, Australia, July 27, 2021 /PRNewswire/ -- Starpharma today announced new data demonstrating that SPL7013, the antiviral agent in VIRALEZE™ nasal spray, is active against the highly transmissible Delta variant of SARS-CoV-2, achieving more than 99.99% reduction of infectious virus in laboratory-based virucidal assays.

The antiviral testing of SPL7013 was conducted in the laboratory of virologist, Professor Philippe Gallay, at The Scripps Research Institute in the US, where previous studies have also demonstrated potent antiviral and virucidal activity of SPL7013 against multiple variants of SARS-CoV-2, including the globally important Alpha, Beta and Gamma 'Variants of Concern'.

Percent reductions of infectious virus achieved with 10 mg/mL SPL7013 (the concentration in VIRALEZE™) are shown in the table below.

Virus:
SPL7013†
Incubation
Time
Percent Reduction of Infectious Virus vs Virus Control^
USAlphaBetaGammaDeltaKappa
30 seconds>99.9%>99.9%>99%>99%>99.99%>99.9%
1 minute>99.9%>99.9%>99%>99%>99.99%>99.9%
5 minutes>99.9%>99.99%>99.9%>99.9%>99.99%>99.9%
15 minutes>99.99%>99.99%>99.99%>99.99%>99.999%>99.99%
30 minutes>99.99%>99.99%>99.99%>99.99%>99.999%>99.99%

† 10 mg/mL SPL7013; ^ virus without exposure to SPL7013

In commenting on the significance of these new findings, internationally recognised virologist, Professor Philippe Gallay from the Scripps Research Institute, said:

"SARS-CoV-2 variants continue to emerge and dominate new infections worldwide. These variants have changes in several viral proteins, including in the spike protein that is essential for the virus to infect its host cell.

"It is remarkable that SPL7013 has demonstrated potent anti-SARS-CoV-2 activity against the broad-spectrum of Variants of Concern, Alpha, Beta, Gamma, and now importantly Delta, and Variant of Interest, Kappa, in vitro. SPL7013 acts as a barrier to viral infection and its broad-spectrum activity demonstrates its resilience against a rapidly changing target.

The Delta variant has been reported to be about 60% more transmissible than the already highly infectious Alpha variant[1], and is now the most common variant in India and the UK, where it accounts for more than 90% of new cases.[2]

Dr Jackie Fairley, CEO of Starpharma, commented: "We are very pleased to confirm the rapid virucidal activity of SPL7013, with greater than 99.99% reduction of infectious virus in just 30 seconds against the Delta variant."

[1] https://www.nature.com/articles/d41586-021-01696-3

[2] https://covariants.org/variants/21A.Delta

Source : Starpharma

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 



Consumer NZ: Buy-now, Pay-later Raking In $10m+ In Late Fees Annually

A Consumer NZ survey has found buy-now, pay-later services are costing shoppers more than $10 million a year in late fees. Close to four out of 10 Kiwi consumers use buy-now, pay-later services, such as Afterpay, Laybuy and Zip... More>>

Westpac: Catherine Mcgrath Appointed New Zealand CEO

Westpac Group CEO Peter King and the Westpac New Zealand Board today announced the appointment of Catherine McGrath as Chief Executive Officer, Westpac New Zealand... More>>


Amazon: AWS To Open Data Centres In New Zealand

Today, Amazon Web Services (AWS), announced plans to open an infrastructure region in Aotearoa New Zealand in 2024. The new AWS Asia Pacific (Auckland) Region will consist of three Availability Zones (AZs) and join the existing 81 Availability Zones across 25 geographic AWS Regions at launch... More>>

ALSO:



Statistics: Surge In Imports Results In Record Monthly Trade Deficit
Imports increased $1.8 billion in August 2021 compared with August 2020, resulting in a record monthly trade deficit of $2.1 billion, Stats NZ said today. Exports were little changed, down $42 million. "This is a larger deficit than normal because of higher values for imports.. More>>

Fonterra: Completes reset, announces annual results and long-term growth plan out to 2030

Fonterra Co-operative Group Limited today announced a strong set of results for the 2021 financial year, reflected in a final Farmgate Milk Price of $7.54, normalised earnings per share of 34 cents and a final dividend of 15 cents... More>>


Statistics: GDP rises in the June 2021 quarter

Gross domestic product (GDP) rose by 2.8 percent in the June 2021 quarter, following a 1.4 percent increase in the March 2021 quarter, Stats NZ said today. June 2021 quarter GDP was 4.3 percent higher when compared with the December 2019 quarter... More>>